Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents.
Eur J Cancer
; 139: 92-98, 2020 11.
Article
em En
| MEDLINE
| ID: mdl-32979647
ABSTRACT
BACKGROUND:
Baseline tumour burden is a prognostic factor for patients with melanoma and non-small-cell lung cancer treated with immunotherapy. However, no data are available on its role in other solid tumours, nor for treatment with next-generation immunoncology agents (NGIOs).METHODS:
We reviewed data of patients with any solid tumour consecutively treated at our institution from August 2014 to March 2019, who received ≥1 dose of immune checkpoint inhibitor and/or NGIO within phase 1 trials. Baseline tumour burden was calculated as ∑i Response Evaluation Criteria in Solid Tumours 1.1 baseline target lesions (baseline tumour size [BTS]) or as sum of all measurable baseline lesions (total tumour burden [TTB]); the impact of both parameters on treatment outcomes was investigated.RESULTS:
One hundred fifty patients were included in the analysis. Median BTS and TTB were 79 mm and 212 mm, respectively. Objective response rate was found significantly associated with BTS (p < 0.001) and TTB quartiles (p = 0.006), with response rates progressively increasing with decreasing tumour burden quartiles. Both progression-free survival (PFS) (p = 0.001) and overall survival (OS) (p < 0.001) were significantly associated with BTS quartiles, with 26% of the patients progression-free and 56% alive at 12 months in the lower BTS quartile, compared with 3% and 24%, respectively, in the upper quartile. TTB was also significantly associated with OS (P = 0.01) and borderline-significant for PFS (p = 0.07). Multivariate analysis confirmed that baseline burden, also considered as continuous variable, is independently associated with PFS and OS, when assessed with BTS (p = 0.001 and p < 0.001) and TTB (p = 0.007 and p < 0.001).CONCLUSIONS:
Lower baseline tumour burden is associated with better outcomes in patients with cancer treated with novel immunotherapies.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carga Tumoral
/
Antineoplásicos Imunológicos
/
Neoplasias
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article